Clinical significance of expression and amplification of the DcR3 gene in pancreatic carcinomas

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 2, 2012, Pages 719-724

  Zhou, Jian ^a   Song, Shi Duo ^a   Li, De Chun ^a   Zhou, Jin ^a   Zhu, Dong Ming ^a   Zheng, Shi Ying ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

DcR3; ELISA; Immunohistochemistry; Pancreatic carcinoma; PCR

Indexed keywords

DECOY RECEPTOR 3; MESSENGER RNA; TNFRSF6B PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE AMPLIFICATION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PANCREAS; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREAS; PANCREATIC NEOPLASMS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84866454447     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.2.719     Document Type: Article

References (24)

1. Anderson GL, McIntosh M, Wu L, et al (2010). Assessing lead time of selected ovarian cancer biomarkers. a nested case-control study. J Natl Cancer Inst, 102, 26-38.
2. Arakawa Y, Tachibana O, Hasegawa M, et al (2005). Frequent gene amplification and overexpression of decoy receptor 3 in glioblastoma. Acta Neuropathol, 109, 294-8.
3. Bai C, Connolly B, Metzker ML, et al (2000). Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci, 97, 1230-5.
4. Bamias G, Siakavellas SI, Stamatelopoulos KS, et al (2008). Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis. Clin Immunol, 129, 249-55.
5. Chen G, Luo D (2008). Expression of decoy receptor 3 in liver tissue microarrays. Natl Med J India, 21, 275-8.
6. Chen G, Luo DZ, Wang Y (2007). Relationship between expression of decoy receptor 3 and apoptosis in hepatocellular carcinoma. Zhonghua Binglixue Zazhi, 36, 113-7.
7. Chen L, Tian X, Li W, et al (2009). Expressions of Fas/DcR3 and RGD-FasL mediated apoptosis in pituitary adenomas. Neurol India, 57, 28-30.
8. Connor JP, Felder M (2008). Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance. Gynecol Oncol, 111, 330-5.
9. Gill RM, Hunt JS (2004). Soluble receptor (DcR3) and cellular inhibitor of apoptosis-2 (cIAP-2) protect human cytotrophoblast cells against LIGHT-mediated apoptosis. Am J Pathol, 165, 309-17.
10. Hsu TL, Wu YY, Chang YC, et al (2005). Attenuation of Th1 response in decoy receptor 3 transgenic mice. J Immunol, 175, 5135-45.
11. Li H, Zhang L, Lou H, et al (2005). Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus. Am J Clin Pathol, 124, 282-7.
12. Li W, Zhang C, Chen C, et al (2007). Correlation between expression of DcR3 on tumor cells and sensitivity to FasL. Cell Mol Immunol, 4, 455-60.
13. Longley DB, Allen WL, McDermott U, et al (2004). The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptpsis in response to antimeabolites, 10, 3562-71.
14. Macher-Goeppinger S, Aulmann S, Wagener N, et al (2008). Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia, 10, 1049-56.
15. Mueller AM, Pedre X, Killian S, et al (2009). The Decoy Receptor 3 (DcR3, TNFRSF6B) suppresses Th17 immune responses and is abundant in human cerebrospinal fluid. J Neuroimmunol, 209, 57-64.
16. Ohshima K, Haraoka S, Sugihara M, et al (2000). Amplification and expression of a decoy receptor for Fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas. Cancer letters, 160, 89-97.
17. Pitti RM, Marsters SA, Lawrence DA, et al (1998). Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature, 396, 699-703.
18. Schwendel A, Richard F, Langreck H, et al (1998). Chromosome alterations in breast cancer carcinomas. frequent involvement of DNA losses including chromosomes 4q and 21q. Br J cancer, 78, 806-11.
19. Shen HW, Gao SL, Wu YL, et al (2005). Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis. World J Gastroenterol, 11, 5926-30.
20. Shi G, Wu Y, Zhang J, Wu J (2003). Death decoy receptor TR6/DcR3 inhibits T cell chemotaxis in vitro and in vivo. J Immunol, 171, 3407-14.
21. Takahama Y, Yamada Y, Emoto K (2002). The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer, 5, 61-8.
22. Wu Y, Han B, Sheng H, et al (2003). Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int J Cancer, 105, 724-32.
23. Yang CR, Hsieh SL, Teng CM, et al (2004). Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. Cancer Res, 64, 1122-9.
24. You RI, Chang YC, Chen PM, et al (2008). Apoptosis of dendritic cell induced by decoy receptor 3(DcR3). Blood, 111, 1480-8.